Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.

ABSTRACT:

Importance

Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options.

Objective

To prospectively assess the benefits and toxic effects of SABR in this patient population.

Design, setting, and participants

This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022. Patients aged 18 years or older with fibrotic ILD and a diagnosis of T1-2N0 NSCLC who were not candidates for surgical resection were enrolled.

Intervention

Patients were t

SUBMITTER: Palma DA 

PROVIDER: S-EPMC10921346 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature